Funds are being used to advance
physiologically-responsive music therapies
Sync Project, Inc., a Boston-based company developing music as a
personalized treatment across a range of conditions, is
accelerating development of its physiologically-responsive music
health platform. To date, Sync Project has raised $5 million in
financing from investors Reid Hoffman, Greylock Partners (via
Discovery Fund), Esther Dyson, David Shaw, Digital Garage, and
PureTech Health. The company aims to validate interventions in both
large-scale consumer experiments and controlled clinical studies in
conditions such as stress, sleep, anxiety, and pain.
“Developing music as precision medicine requires the right mix
of people and funding that bridge consumer technology, music, and
biotech,” said Marko Ahtisaari, CEO and Co-founder. “Our investors,
advisors, and team are just such a mix. With the support of our
investors, Sync Project is accelerating the development and
validation of generative music for health.”
“We are excited about the Sync Project team and how they are
using artificial intelligence to create a new kind of personalized
music that responds to your physiology to improve health,” said
Reid Hoffman, partner at Greylock Partners.
Sync Project is building a unique data set on the biometric
impact (e.g., heart rate, brain activity, and sleep patterns) of
certain structural properties of music (e.g., beat, key, and
timbre). Datasets generated through Sync Project’s consumer
initiatives will be further validated through controlled clinical
trials in individuals suffering from sleep disorders, anxiety, and
pain, among others. Sync Project aims to commercialize the clinical
applications of this platform and deliver a personalized, low-cost,
non-invasive therapy, across a range of conditions.
Sync Project’s generative music platform is based on scientific
research into the health effects of music. Recent research has
shown that music can modulate neural systems like the dopamine
response, autonomic nervous system, and other key pathways related
to stress, movement, learning, and memory. This body of research
shows that music affects some of the same neural pathways that are
regulated by pharmaceuticals such as psychostimulants and suggests
that music may hold significant therapeutic potential.
Earlier this year, Sync Project launched unwind.ai, the first
global experiment using algorithmically-generated music to
potentially improve relaxation prior to sleep. Anyone with a
smartphone can participate free of charge and contribute to a
global data set on how music affects stress. Designed in
collaboration with critically-acclaimed musicians, Sync Project’s
generative music is personalized to an individual’s unique
physiology.
About Sync ProjectSync Project is developing music as
precision medicine. Sync Project’s generative music platform builds
on scientific research into the health effects of music with a
unique data set and machine learning that analyses musical
attributes (like tempo and timbre) and their impacts on biometrics
(like heart rate, brain activity, and sleep patterns.) Insights
from Sync Project’s consumer initiatives will be further validated
through controlled clinical trials in individuals suffering from
sleep disorders, anxiety, and pain, among others. Sync Project aims
to commercialize the clinical applications of their platform and
deliver a personalized, low-cost, non-invasive therapy, across a
range of conditions. Sync Project was co-founded by Marko
Ahtisaari, Yadid Ayzenberg, Ketki Karanam, and PureTech Health
(LSE: PRTC; www.puretechhealth.com).
Sync Project’s advisors and Board comprise a distinguished and
diverse team of science, music, health and technology experts
committed to uncovering the untapped potential of music’s ability
to improve health: Robert Zatorre, Ph.D., Professor of Neurology
and Neurosurgery at the Montreal Neurological Institute at McGill
University; Adam Gazzaley, M.D., Ph.D., Director of the
Neuroscience Imaging Center and Professor of Physiology, Psychology
and Psychiatry at the University of California, San Francisco;
Tristan Jehan, Ph.D., Founding Chief Technology Officer of The Echo
Nest (Spotify); Peter Gabriel, six-time Grammy Award-winning
British singer-songwriter; Annie Clark (St. Vincent), award-winning
American singer-songwriter and multi-instrumentalist; Jon Hopkins,
classically trained British pianist, critically acclaimed recording
artist, Ivor Novello nominated composer of film scores, and
prominent producer/collaborator; Esa-Pekka Salonen, Principal
Conductor and Artistic Advisor of the Philharmonia Orchestra in
London and Conductor Laureate for the Los Angeles Philharmonic; and
Board Members Joi Ito, Director of the Massachusetts Institute of
Technology Media Lab, Marjorie Scardino, DBE, FRSA, Chairman of the
MacArthur Foundation, Board member of Twitter and former CEO of
Pearson, Steven Holtzman, CEO of Decibel Therapeutics, and Daphne
Zohar, Co-Founder and the Chief Executive Officer of PureTech
Health. For more information visit syncproject.co or connect
with us on Twitter @syncprojectco.
Forward Looking StatementThis press release contains
statements that are or may be forward-looking statements, including
statements that relate to the company's future prospects,
developments and strategies. The forward-looking statements are
based on current expectations and are subject to known and unknown
risks and uncertainties that could cause actual results,
performance and achievements to differ materially from current
expectations, including, but not limited to, those risks and
uncertainties described in the risk factors included in the
regulatory filings for PureTech Health plc. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law and regulatory requirements, neither the company
nor any other party intends to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170516006817/en/
PureTech HealthAllison Mead, +1
617-651-3156amead@puretechhealth.com
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Apr 2024 to May 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From May 2023 to May 2024